Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
* STB-C017 is an IDO/TDO dual inhibitor, derived from Syntekabio's proprietary drug discovery artificial intelligence solution, demonstrated powerful immuno-oncologic effect. * Triple combination therapy of STB-C017, PD-1, CTLA-4 immune checkpoint inhibitors (ICIs) presented complete remiss...
2020-05-15 12:01
3332
Syntekabio Presents Nonclinical Data of immuno-oncologic agent STB-C017 at the 2020 AACR meeting
DAEJEON, South Korea, May 15, 2020 /PRNewswire/ -- Syntekabio (KOSDAQ: 226330), an AI and NGS based drug development company, presented the result of STB-C017 animal experiments, a small molecule IDO/TDO dual inhibitor derived by Syntekabio's AI drug discovery solution, at the 2020 American Assoc...
2020-05-15 12:01
3799
